Cancer vaccine plus immunotherapy for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a cancer vaccine (called TTV) combined with a PD-1 inhibitor (a type of immunotherapy) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this new combination helps shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced solid tumor cancer that has grown despite standard treatments or you cannot get those treatments.
- You have at least one tumor that can be measured on a scan (a pea-sized mass or bigger).
- You are able to care for yourself (ECOG score 0–2) and your doctor expects you to live more than 12 weeks.
- You are not pregnant, breastfeeding, or planning to become pregnant; you agree to use birth control if needed.
- You are willing to follow the study plan and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized vaccine made from your own cells to help your immune system attack tumor-specific targets. It may be an option if standard treatments have stopped working or caused side effects you can't tolerate.
This trial tests whether a personalized mRNA vaccine, given with pembrolizumab, can help people with advanced solid tumors by training the immune system to recognize cancer. It is mainly for patients whose tumor tissue matches specific genetic and immune patterns, and who meet key safety and infection requirements.
This trial tests a personalized mRNA vaccine (InnoPCV) designed from your own tumor's genetic profile to train your immune system to fight advanced solid tumors. It is for people who have not had tumor vaccines or CAR-T therapy before and can provide a tumor sample for customized vaccine creation.
This trial tests a combination of two cell-based therapies (SCTB41 and SCTB39-1) with or without standard cancer treatments for advanced solid tumors. The goal is to see if this approach helps slow or shrink tumors while being safe enough to use in patients.
This trial tests a new personalized cancer vaccine (LM103) combined with an immunotherapy drug (PD-1) for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this combination is safe and can help shrink tumors.
This Phase 1 trial tests a cancer vaccine (VAX014) injected directly into a tumor, given alone at first and then with an immune checkpoint medicine (nivolumab or pembrolizumab). It aims to see how well this approach is tolerated and may help shrink advanced solid tumors after other treatments stopped working.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.